May 19 (Reuters) - GT Biopharma Inc GTBP.O:
GT BIOPHARMA ADVANCES GTB-3650 PHASE 1 TRIAL TO COHORT 2 FOLLOWING SUCCESSFUL INITIAL HUMAN DOSING AND EVIDENCE OF EARLY IMMUNE ACTIVATION SIGNALS
GT BIOPHARMA INC - NO SAFETY ISSUES IN COHORT 1, COHORT 2 PROCEEDS
GT BIOPHARMA INC - DETAILED PHASE 1 RESULTS EXPECTED LATER IN 2025
Source text: ID:nGNXnxzFt
Further company coverage: GTBP.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.